Rana McKay
@DrRanaMcKay
Followers
4,025
Following
792
Media
382
Statuses
1,236
GU medical oncologist @UCSanDiego , mom, wife, avid runner. Kidney and prostate cancer research. Tweets are my own and not medical advice.
Joined April 2019
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
#LCDLF4
• 231987 Tweets
Cauca
• 140455 Tweets
Costello
• 107797 Tweets
Romeh
• 73607 Tweets
#WWERaw
• 51664 Tweets
Lupillo
• 49138 Tweets
Maripily
• 40287 Tweets
SAROCHA REBECCA ON RED CARPET
• 35632 Tweets
#ラヴィット
• 30050 Tweets
FELIX ENAMORA A BARCELONA
• 29735 Tweets
STRAY KIDS HITS HOT100
• 26881 Tweets
BLINDAJE FURIOSO
• 25290 Tweets
Scarlett Johansson
• 23954 Tweets
定額減税
• 20160 Tweets
ビットコイン
• 14013 Tweets
WELCOME TREASURE TO THAILAND
• 13994 Tweets
給与明細
• 11458 Tweets
Fani Willis
• 11347 Tweets
金額明記
• 10795 Tweets
Lyra
• 10790 Tweets
Excited to move forward the Samurai trial of SBRT + IO to patients with advanced RCC with primary intact.
@dr_aschmidt
@DrChoueiri
@NRGonc
9
34
118
Exciting to launch PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Robust database with now >2000 patients with detailed clinical data linked to genomic.
@AarmstrongDuke
@TDorffOnc
0
35
100
With
@umangtalking
@neerajaiims
at the
#ESMO22
poster session 👉Congrats for the GU Best poster award. Always amazing research from
@Huntsman_GU
team.
@OncoAlert
@urotoday
@huntsmancancer
2
32
98
Truly an honor to receive this designation alongside extraordinary colleagues and mentors. Thank you
#ASCO
.
#FASCO
@UCSDCancer
Join us in congratulating the following members on earning the Fellow of ASCO (FASCO) distinction this quarter! We're grateful for your extraordinary volunteer service, dedication, and commitment to ASCO. More about FASCO:
6
10
53
22
5
97
We are so excited to welcome
@YuWeiChenMD
to
@UCSDCancer
!! Rising star in GU oncology!!
#ASCO2023
8
10
85
Important criteria for genetic testing in patients with RCC.
1
34
80
Absolutely honored to be recognized as the MOASC researcher of the month. Working to push the field forward to make sure our patients live longer and live better! That is my guiding light!
@MOASC_Office
@NRGonc
@ALLIANCE_org
What a delight to interview
@DrRanaMcKay
- a true force of nature. She has done so much to reshape the landscape of GU cancers through innovative studies, which is why we picked her as
#August
@MOASC_Office
#ResearcherOfTheMonth
. Listen here for details of
#SAMURAI
&
#RADICAL
!
1
10
51
6
6
78
It's time for ASCO elections. This is a special year as my colleague and friend
@montypal
is on the ballot for ASCO nominating committee. I can't think of a more hardworking, collaborative, and positive individual to represent ASCO.
@OncoAlert
@DrChoueiri
0
22
76
Landmark day in kidney cancer history. Adjuvant pembrolizumab now FDA approved in RCC at high risk of relapse post nephrectomy. Game changer. Congrats
@DrChoueiri
@tompowles1
1
15
73
177Lu-PSMA finally receives FDA approval! Huge breakthrough for patients. Indication in PSMA positive disease post ARTA and taxane.
@morr316
@ALLIANCE_org
@DrScottTagawa
@PCFnews
0
13
69
What a small world! Ran into amazing GU rockstar
@TiansterZhang
at meeting in Newport! Welcome to the west coast!
@montypal
@TDorffOnc
2
3
68
Excellent talk by
@PamSharmaMDPhD
on novel checkpoints and rethinking trial design to integrate rich tissue correctives to allow for more rationally designed future studies.
@DrChoueiri
@BraunMDPhD
1
16
67
Carlsbad 1/2 marathon was awesome. First race of the triple crown. No scenic road side pics this week because I was in race mode. PCH1 was beautiful. All I got are the event pics. Great to finally run without a stroller!!
@TylerSbrt
@AdamSharpMedOnc
12
1
66
Love the
@ALLIANCE_org
community.
@morr316
has dedicated years of endless service and mentorship to this group. A true leader and mentor. Thank you!!
@mishabeltran
@AarmstrongDuke
@DrRosenbergMSK
@DrChoueiri
@NCIDirector
@NCIResearchCtr
@AtishChoudhury
@charlesryanmd
1
10
62
Exciting to activate the Samurai trial. Long time in the making looking at role of SBRT to the primary tumor with IO for patients with mRCC!
@whallradonc
@felixfengmd
@NRGonc
@BradMcG04
@DrChoueiri
@UCSDRadMed
@TylerSbrt
NRG-GU012 Activation! Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI).
@whallradonc
@DrRanaMcKay
@TheCTSU
@theNCI
Read more:
2
21
66
2
12
57
So proud of Sharon Choi, our amazing fellow!! Presenting work on Wnt signaling. Happy to have her join our team this fall!!
#GU24
@UCSDCancer
1
5
56
The arrival of
@montypal
at the
#OncLiveSOSS
. So excited. What an amazing colleague, friend, researcher, mentor!
@DrChoueiri
@bergsa83
@PGrivasMDPhD
@neerajaiims
2
9
56
We need more trials investigating this approach in RCC. IO combo +/- SBRT to all visible sites of disease.
@DrChoueiri
@NRGonc
@Dr_RayMak
A pair of clinical trialists from the UK share their views about SABR for oligometastatic disease. 🇬🇧
#radonc
@IyengarPuneeth
@CJTsaiMDPhD
#WhereIsDavidPalma
16
20
55
4
12
53
@avasaidian
is a rising star! Congrats on this amazing work and merit award from our multi-institutional series of IO pre CRN.
@UCSDHealth
@ASCO
@endourologyucsd
@cjkane10
@AdityaBagrodia
2
4
53
Finally published. Data in a response adaptive IO strategy in RCC. Lower CR rates. Lower rates of CR/PR conversion. Speaks to early upfront dual blockade in those who can receive it.
@DrChoueiri
@BradMcG04
@LaurenCHarshman
1
11
54
This is now the third negative adjuvant IO trial in RCC (Prosper, IMmotion010, Checkmate 914) after the initial landmark data from KN 564. Need to understand the data to reduce these findings to practice.
@DrChoueiri
@montypal
3
15
54
Risking dropping my phone off the balcony for this amazing pic with the one and only
@PGrivasMDPhD
@neerajaiims
@montypal
@DrChoueiri
@AlbigesL
#ESMO2022
0
2
51
It’s Kidney Cancer Awareness month!
@UCSD_Urology
@UCSDCancer
Let’s Orange Up!! Support Kidney Cancer Research and Awareness!
@kidneycan
@IKCCorg
@DrChoueiri
@montypal
@endourologyucsd
@cjkane10
@CalifanoMd
@AdityaBagrodia
2
6
51
Amazing turnout at the Prostate Cancer Patient Summit. Really connecting with our community!!
@UCSDHealth
@UCSDCancer
@ThePCCTC
@PCFnews
1
7
49
Can’t wait for GU ASCO!! Join us for the GU tumor board in RCC. Jan 25 from 7-9 pm!
@tompowles1
@DrChoueiri
@AlbigesL
1
9
50
Support the Alliance RADICAL trial of cabozantinib with or without radium-223 for RCC with bone mets. Currently accruing!
@ALLIANCE_org
1
19
49
Absolutely amazing to see the first life prolonging adjuvant therapy in RCC. We are not just delaying progression but likely preventing it!
@DrChoueiri
@OncoAlert
Historical time in RCC!!!!
Major Breakthrough for Renal Cell Carcinoma Patients!
🌟Pembrolizumab Achieves Remarkable Milestone in RCC Treatment
🎯 Pembrolizumab becomes the FIRST therapy to showcase a significant improvement in overall survival (OS) as an adjuvant treatment for
0
45
143
0
7
48
Thank you
@Uromigos
for an awesome debate! Doublets and triplets are the new standard in mHSPC.
Our prostate cancer debate with Rana McKay and Kim Chi covers 1st line doublet vs triplet therapy. This video is a quick summary - the podcast has the detail...
1
12
47
1
9
47
Kicking off
#AUA23
with the one and only
@JoshLangMD
taking science in Chicago!
@DrChoueiri
@felixfengmd
3
0
47
A great time in RCC with many new options for patients and a changing paradigm in the field. Thank you Monty for the opportunity.
@montypal
@DrChoueiri
@urotoday
The evolving landscape for the frontline treatment of metastatic RCC: VEGF targeted therapy with immunotherapy and IO-IO combinations,
#OMNIVORE
and more.
@DrRanaMcKay
@UCSDHealth
interview w/
@montypal
@cityofhope
on UroToday:
#RenalCancer
0
4
11
2
5
47
Today marks the moment in history where the SOC changed in the treatment of mUC! A victory for our patients!
#ESMO2023
@PGrivasMDPhD
@tompowles1
@DrChoueiri
@MattGalsky
@apolo_andrea
@shilpaonc
@DrRosenbergMSK
Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)
#ESMO2023
23
508
1K
0
13
47
We are actively recruiting an academic medical oncologist to join our Genitourinary Malignancies Program at UCSD. Application link attached:
0
13
47
Radical is officially activated!! Exploring the role of radium-223 in patients with advanced RCC with bone metastases receiving cabozantinib. Support this
@ALLIANCE_org
trial.
@DrChoueiri
@Daniel_J_George
@TiansterZhang
@morr316
@KCA_Journal
NEW TRIAL! .
@DrRanaMcKay
@UCSanDiego
leads
@ALLIANCE_org
trial A031801 to see if adding radium-223 dichloride to the usual cabozantinib treatment helps patients w/renal cell cancer that has spread to the bone. Learn more:
#RCCSM
#NCI
#NCTN
#CancerResearch
0
4
6
4
12
43
Great strides for patients with VHL-disease! FDA approves belzutifan for patients with cancers with VHL disease. Two FDA approvals in one week!
@kcCURE
@DrChoueiri
0
11
45
At the
@UCSDHealth
@UCSDCancer
Prostate Cancer Community Think Tank. Partnering with our patients to understand gaps in the field. Building solutions with patients.
@AdityaBagrodia
@vjake20
@ThePCCTC
@UCSDCancer_COE
1
9
42
Excited to meet these amazing individuals through the
@ASCO
Leadership Development Program. Looking forward to a phenomenal year growing and learning!
3
1
44
Landmark data from KN564 presented by
@DrChoueiri
- positive DFS, strong OS signal. We finally enter into a new adjuvant era in RCC.
@ASCO
#asco2021
0
11
43
We evaluated the impact of ADT on outcomes in patients with prostate cancer and
#COVID19
. Amazing contributions from this powerhouse team!
@COVID19nCCC
@PGrivasMDPhD
@DrChoueiri
@hemoncwarner
@shilpaonc
1
18
42
The combination of cediranib + olaparib improved RPFS in men with CRPC. Effect most pronounced in HRD patients.
@ASCO
1
12
42
Support the Radical trial of cabozantinib +/- radium-223 for patients with bone mets and RCC.
@ALLIANCE_org
@DrChoueiri
Just in
@KCA_Journal
👉🏻1/3rd patients with mRCC kidneycancer have bone mets. Scant data on development, prevention, prognosis and treatment of skeletal related events (SREs) in mRCC👉🏻Excellent systemic review by
@PBarataMD
@bilenma
& team.
@KidneyCancer
2
34
49
0
18
42
Looking forward to an exciting
#ESMO2022
Lots of exciting data in GU with multiple long awaited phase 3 studies being presented.
@DrChoueiri
@AlbigesL
@TiansterZhang
@montypal
@BradMcG04
@_ShankarSiva
@tompowles1
@drenriquegrande
@PGrivasMDPhD
@neerajaiims
0
8
43
Hanging out with
@wandering_gu
and
@JoshLangMD
in PA discussing prostate cancer! Fun times seeing these rockstars today!
1
0
42
Announced today CheckMate 9ER positive! Testing combination of nivolumab + cabozantinib for frontline RCC. Complicates the front line space but more options for patients.
@DrChoueiri
@KidneyCancer
1
14
40
Check out our work examining different cellular states in advanced prostate cancer to identify strategies for therapeutic targeting.
#PCFRetreat19
#ProstateCancer
1
7
40
Words of wisdom from my dear patient: Take care of your body as though you would live forever, take care of your soul as though you would die tomorrow, and do what’s right when no one is looking. A true message for life. Going up in my office.
@UCSDHealth
2
7
40
Awesome Saturday night with
@archana_ajmera
and Nancy Moldawer on evolving strategies in RCC.
@PeerView
@KidneyCancer
0
13
40
So honored to support this amazing organization driven by passionate patient advocates who are the heart and soul of this group. They are the fuel for all the amazing work to cure kidney cancer for all!
@kidneycan
@DrChoueiri
@HHammersMD
@montypal
Can't begin to describe
@DrRanaMcKay
's contributions to
#KCRS22
!
- Abstract Committee leadership
- Superb session moderation
- Outstanding talk on Novel Drugs in Early Development
-
#RocktheRun
Racer
Thank you, Rana, for all you do to
#acceleratecures
for
#kidneycancer
! 🤩
1
5
35
0
2
40
Incredible story of one of our patients on the Radical trial investigating cabozantinib and radium-223 in patients with RCC with bone metastases.
@kcCURE
@KidneyCancer
@ALLIANCE_org
@DrChoueiri
5
12
40
Look who I found this morning at the
@asco
editorial board breakfast! So great to connect with awesome friends!!
@PGrivasMDPhD
@neerajaiims
0
5
40
Finally time to celebrate! Last ASCO abstract submitted with 51 minutes to spare!! Exciting times!
@ASCO
@UCSDHealth
0
1
40
Another study adding to the compendium of data highlighting link between cfDNA detection and recurrence for those with localized disease.
1
14
40
Landmark positive biomarker trial in prostate cancer highlighting ALL men with CRPC should be tested for HR gene alterations.
@PCF_Science
@ThePCCTC
0
23
39
Getting ready for the Prostate Cancer Patient Summit
@UCSDCancer
@ThePCCTC
@PCF_Science
@AdityaBagrodia
Looking forward to great community engagement
0
2
37
So proud of
@justinepanian
on her amazing work investigating CRN post IO. Huge team effort!
@ASCO
@UCSanDiego
@bergsa83
@deepak_kilari
@spsutkaMD
3
9
38
Words can’t even express how proud I am of
@justinepanian
for leading a large multi-institutional project looking at pathologic outcomes at CRN post IO. She is an amazing clinician, researcher and person.
@UCSDCancer
@UCSDHealth
@UCSDMedSchool
Thankful to have the best mentor for the past 5 years!
@DrRanaMcKay
It was an honor getting to present our CRN post-IO study on stage together at
#KCRS22
!
@kidneycan
@UCSDMedSchool
@UCSDCancer
1
6
47
3
2
38
The
@ALLIANCE_org
RADICAL trial is testing cabozantinib +/- radium-223 in patients with RCC and bone mets. Critical study for this high risk population. Thank you
@DrChoueiri
@Daniel_J_George
@morr316
for all the mentorship in bringing this study to our patients.
#IKCSNA22
0
12
37
Rock star bladder panel at
#uroamigoslive
in beautiful Nashville! Amazing hosts with
@tompowles1
@brian_rini
@MattGalsky
@shilpaonc
@DrRosenbergMSK
0
5
37
0
4
37
FDA approves NivoCabo for front line advanced RCC. Strong work
@DrChoueiri
@apolo_andrea
1
12
37
Prosper RCC is open and actively recruiting patients. Seeking to answer an important question regarding the role of perioperative nivolumab.
@ALLIANCE_org
@eaonc
@SWOG
@DrChoueiri
@TiansterZhang
0
14
37
Good morning
@ASCO
! Beautiful run watching sunrise on the lake!
@TylerSbrt
@DrChoueiri
@AdamSharpMedOnc
@BradMcG04
@maughanonc
3
4
37
Who wears orange on St. Patrick’s Day.
@UCSDCancer
promoting Kidney Cancer Awareness month! Such an amazing collaborative group! Orange up!!
@KidneyCancer
@kidneycan
2
5
36
Lebanese food is so beautiful and made from the heart!! Food for the soul. I picture my grandma making these delicacies one by one. One of my favorites is Shish Barak. Each dumpling made by hand one by one.
@DrChoueiri
@chadinabhan
1
0
36
Amazing to have
@mishabeltran
speaking at the
@UCSDCancer
Sparkathon event. Sharing her experience as a translation scientist and work on NEPC.
@PCFnews
@DanaFarber
1
4
35
Absolutely amazing mentorship through the Alliance GU committee. What a phenomenal group of individuals really promoting the success of trainees and junior faculty.
@DrChoueiri
@morr316
@Daniel_J_George
Mary-Ellen Taplin and more!
@ALLIANCE_org
The
@ALLIANCE_org
#GU
is about mentoring next group of leaders! These 3 trials I’m serving as co-chair/mentor are led by 3 amazing physician-trialists:
#PDIGREE
by
@TiansterZhang
#IMAGINE
by
@xiaoweimd
&
#RADICAL
by
@DrRanaMcKay
Kudos to
@morr316
@DrRosenbergMSK
@Daniel_J_George
3
22
89
2
4
33
Beautiful morning in Philly. Nothing like going out for a run.
@KidneyCancer
@kidneycan
0
4
34
Amazing meeting with four phase 3 studies being reported and practice changing data across GU Cancers. Process for patients.
@DrChoueiri
@montypal
@DRathkopf
@MattGalsky
@motzermd
What an amazing
@ASCO
#GU21
with new advances in
#GU
#Oncology
, and two
@NEJM
+ one
@TheLancet
papers published online during the meeting!! Truly outstanding!! Congratulations to all!!
@tompowles1
@montypal
@motzermd
@urotoday
@OncoAlert
@TiansterZhang
@DrRanaMcKay
@DanaFarber
4
67
239
0
7
33
Getting ready for what is sure to be a packed house at
#ESMO2022
Non Prostate GU oral session!
@tompowles1
@drenriquegrande
@myESMO
@DrChoueiri
@TiansterZhang
@DrDanielHeng
@apolo_andrea
@BradMcG04
1
3
33
Thank you for taking a stand!
Colleagues
In Response to the invasion of Ukraine🇺🇦, the
@OncoAlert
🚨network will be pulling out of ALL collaborations & congresses in Russia
We're non political, but we must take a stand against the injustices & aggression being directed towards Ukraine‼️
Best,
The Network🌐
249
113
446
4
7
32
Partnering with our nursing team on optimizing treatment for patients with RCC!
@PeerView
@archana_ajmera
1
11
32
Radical trial of radium-223 + cabozantinib for patients with RCC with bone metastases. Currently accruing through the NCTC.
@ALLIANCE_org
@KidneyCancer
@kidneycan
1
11
32
I would say more than move the needle…literally changed the entire landscape of RCC management in less than a decade…frontline combination therapies, adjuvant therapies and a move towards developing clinically relevant biomarkers, while mentoring future generations.
Proud of
@DrChoueiri
@DanaFarber
, who will be honored as a "Giant of Cancer Care" (
@GCCAwards
) alongside other legends in the field. Incredible to see what he has/is accomplishing; he's moved the needle enormously in the field of
#kidneycancer
!
14
40
151
1
1
32
What do we mean by equality and equity? How can we level the playing field! Especially in advanced diagnostics and genomics in prostate cancer.
0
5
32
Amazing! I now get excited when I see a sarcomatoid RCC and the increased likelihood of a durable response with IO!
Just now! Efficacy and Safety of
#Nivolumab
Plus
#Ipilimumab
vs
#Sunitinib
in First-Line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma by
@DrChoueiri
@Cidjeronimo
@montypal
@brian_rini
et al. Congratulations!
5
106
230
1
5
31
PDL1 has not been the biomarker that we wanted in bladder cancer.
#Uroamigoslive
@PGrivasMDPhD
@shilpaonc
@tompowles1
1
7
31
Vail workshop 2013 reunion! Amazing group of individuals!
@brian_rini
@Uromigos
@PGrivasMDPhD
@FaltasLab
2
2
31
0
2
9
1
3
31
Can’t think of a more deserving individual! Bringing people together across the globe with the mission to improve cancer outcomes for all patients.
@DrChoueiri
congrats!
Dear friends
An Amazing way to start
#ESMO21
Our biggest heartfelt CONGRATULATIONS to the Heart & Soul of your
@OncoAlert
network
@DrChoueiri
who has just been named a GIANT of
#Cancer
care
@GiantsofCC
@GCCAwards
We are SO PROUD & congratulate him on this well deserved award!
18
40
154
0
2
31
@TylerSbrt
at NRG meeting discussing opportunities for evaluation of dQTLs predicting somatic tumor alterations.
@NRGonc
@felixfengmd
@PCFnews
2
2
31
Exciting to launch the Maverick trial in mCRPC with amazing scientist
@NimaSharifiMD
Will be the first bio marker study for HSD3B1 adrenal permissive selected patients.
@ThePCCTC
@PCF_Science
7/9 Eligibility includes men w/CRPC w/at least 1 copy of the adrenal-permissive HSD3B1 allele (more active biosynthesis > more likely to benefit). Men get the BMX inhibitor abivertinib + abiraterone. Will have abi-naïve & –progressing cohorts. 9 sites will participate!
@ThePCCTC
2
1
8
0
4
30
History being at
#ESMO2023
where the standard of care shifts to EV+Pembro for frontline mUC!
@tompowles1
@apolo_andrea
@PGrivasMDPhD
@DrChoueiri
@neerajaiims
@montypal
0
10
30
Those with variant histology RCC remain an unmet need. Our study demonstrates clear activity with AtezoBev in this subset.
@DrChoueiri
@BradMcG04
@JCO_ASCO
@UCSDHealth
Proud to present first IIT for combination of VEGF with Immunotherapy in RCC with variant histology in
@JCO
with
@Drchoueiri
@DrRanaMcMay
@DrVaishampayan
@ASCO
@DanaFarber
#RCC
@DanaFarberNews
LINK:
3
40
96
0
4
30
Exciting discussion about adjuvant and neoadjuvant therapy in RCC. Much to be learned from Prosper.
#UroamigosLive
@DrChoueiri
@neerajaiims
@montypal
@TiansterZhang
0
7
29
Amazing work by
@apolo_andrea
led to a series of ground breaking studies in RCC and GU malignancies.
0
8
30
I am so incredibly proud of our UCSD and
@justinepanian
@avasaidian
for their incredible work looking at outcomes of patients with CRN post IO. These ladies are absolutely spectacular.
@OncoAlert
#KCRS
@UCSDCancer
@UCSD_Urology
#KCRS22
Oral Abstract Session:
@justinepanian
@UCSDHealth
reports on the pathologic outcomes at cytoreductive nephrectomy (CN) following immunotherapy in patients with metastatic
#RCC
@DrRanaMcKay
Abstracts:
Register:
@OncoAlert
0
2
8
1
6
30
Kicking off the inaugural
#SOCALGU24
meeting with our patient advocates! It’s why we do what we do!
@BladderCancerUS
@kureit
@kidneycan
@montypal
@UCSDCancer
0
8
31
Fantastic discussion by
@wandering_gu
@UMichUrology
on biomarker testing in prostate cancer.
@UCSD_Urology
@UCSDHealth
1
3
28
@PavlosMsaouel
reviewing pathogenesis of RMC and linking to high intensity exercise.
@KidneyCancer
@kidneycan
2
9
29
Amazing tribute by
@brian_rini
at the
#uroamigoslive
unplugged meeting in Nashville! What an amazing patient advocate, researcher, clinician and friend. Thank you!
0
1
29
Our amazing nurse practitioner
@archana_ajmera
giving a great overview of ADT and strategies to improve side effects of ADT!
@PCFnews
@UCSDCancer
2
3
29
1
5
28
Excellent discussion by
@shilpaonc
on role of VEGF inhibition in urothelial cancer. Support
@ALLIANCE_org
Main-Cav trial.
2
8
28
